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Abstract
Background: Preferred models for the pharmacokinetic analysis of [11C]flumazenil human studies have been
previously established. However, direct translation of these models and settings to animal studies might be
sub-optimal. Therefore, this study evaluates pharmacokinetic models for the quantification of [11C]flumazenil
binding in the rat brain.
Dynamic (60 min) [11C]flumazenil brain PET scans were performed in two groups of male Wistar rats (tracer
dose (TD), n = 10 and pre-saturated (PS), n = 2). Time-activity curves from five regions were analyzed, including
the pons (pseudo-reference region). Distribution volume (VT) was calculated using one- and two-tissue compartment
models (1TCM and 2TCM) and spectral analysis (SA). Binding potential (BPND) was determined from full and simplified
reference tissue models with one or two compartments for the reference tissue (FRTM, SRTM, and SRTM-2C). Model
preference was determined by Akaike information criterion (AIC), while parameter agreement was assessed by linear
regression, repeated measurements ANOVA and Bland-Altman plots.
Results: 1TCM and 2TCM fits of regions with high specific binding showed similar AIC, a preference for the 1TCM, and
good VT agreement (0.1% difference). In contrast, the 2TCM was markedly preferred and necessary for fitting
low specific-binding regions, where a worse VT agreement (17.6% difference) and significant VT differences
between the models (p < 0.005) were seen. The PS group displayed results similar to those of low specific-binding
regions. All reference models (FRTM, SRTM, and SRTM-2C) resulted in at least 13% underestimation of BPND.
Conclusions: Although the 1TCM was sufficient for the quantification of high specific-binding regions, the 2TCM was
found to be the most adequate for the quantification of [11C]flumazenil in the rat brain based on (1) higher fit quality,
(2) lower AIC values, and (3) ability to provide reliable fits for all regions. Reference models resulted in negatively biased
BPND and were affected by specific binding in the pons of the rat.
Keywords: [11C]Flumazenil, Pharmacokinetic modeling, Rat, GABAA receptors, PET
Background
[11C]Flumazenil is a well-established and widely used ra-
diotracer in positron emission tomography (PET) studies
in humans [1] as a GABAA antagonist. It binds to the
benzodiazepine binding site of the GABAA receptor,
allowing PET imaging of [11C]flumazenil uptake to en-
able the in vivo visualization and quantification of pro-
cesses related to neuronal loss and integrity [2, 3]. More
specifically, flumazenil displays comparable levels of
binding to the GABAA receptors containing α1, α2, α3,
or α5 subunits, which is why this compound is consid-
ered to be not subtype-selective [4]. For these reasons,
[11C]flumazenil can be considered a versatile PET tracer
and it has been used in the study and assessment of sev-
eral conditions, such as neuronal damage in head injury
[5], epilepsy [6], stroke-induced penumbral areas of in-
farction [7], and Alzheimer’s disease [8].
The quantification of [11C]flumazenil uptake and bind-
ing is often performed by pharmacokinetic modeling,
with the aid of compartmental models [9]. For the appli-
cation of those models, information on tracer delivery is
needed. This information can be obtained either in a
direct form, by arterial sampling and the construction
of a plasma input function, or in an indirect manner
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making use of a reference tissue devoid of receptors of
interest [10]. Previous human studies [11, 12] evaluated
the performance of some of these models (plasma input
and reference tissue based) and established which ones
provided a more robust and reliable quantification of
[11C]flumazenil receptor binding. For plasma input
methods, the one tissue compartment model (1TCM) was
determined to be the preferred model [11]. Among the
reference-based models for [11C]flumazenil quantification,
the simplified reference tissue model (SRTM) was consid-
ered valid and robust [13], with the use of the pons as the
reference tissue, based on the fact that this region shows a
low density of GABAA receptors [14].
However, the superiority, validity, and accuracy of the
1TCM and the SRTM for the quantification of [11C]flu-
mazenil binding have only been assessed in human studies
and, therefore, are related to the behavior of this radio-
tracer in the human brain. Surprisingly, there has not yet
been a careful assessment of the performance of the differ-
ent pharmacokinetic models for rat studies. Nonetheless,
pharmacokinetic modeling can be of particular relevance
in the pre-clinical setting, since animal studies are often
applied in drug development, longitudinal disease moni-
toring, or treatment response assessment. There, assessing
the full tracer kinetic profile in tissue is preferable above
semi-quantitative measures such as standard uptake
values (SUVs) or SUV ratios (SUVR) [15, 16]. Since ana-
tomical and physiological variations between species can
affect tracer kinetics, the suitability of the clinically appro-
priate kinetic models for [11C]flumazenil brain kinetics
can be questioned. Therefore, the purpose of this study
was to investigate which pharmacokinetic model is most
appropriate for the quantification of [11C]flumazenil bind-
ing in pre-clinical rat studies. In order to do so, we retro-
spectively analyzed PET rat brain data, as well as
simulated data, by a number of different methods, includ-
ing compartmental (plasma input and reference tissue
based) and non-compartmental methods.
Methods
Data from male outbred Wistar-Unilever rats (n = 12)
obtained from Harlan (Horst, The Netherlands) and part
of a pre-clinical study were analyzed. The pre-clinical
study, of which the results will be reported elsewhere, di-
vided the rats into three groups: controls (CRTL, n = 5),
rats displaying neuroinflammation as a result of infection
with the herpes encephalitis virus (HSV, n = 5) [17–19],
and rats pre-saturated with cold flumazenil (PS, n = 2).
For the purpose of this pharmacokinetic modeling study,
rats from the CRTL and the HSV group were com-
bined into one group which received a tracer dose
only (TD, n = 10). The PS group remained unchanged and
as a separate group for additional analysis (Table 1). Al-
though outside the scope of this study, the CTRL and
HSV groups were tested for differences in plasma and
metabolite curves, as well as for regional quantitative
endpoint parameters derived from each tested phar-
macokinetic models and no differences were found
between the two groups, supporting the construction
of the TD group.
All animal experiments were performed according to
the Dutch Law on Animal Experiments and approved by
the Institutional Animal Care and Use Committee of the
University of Groningen (6264B).
PET imaging
Animals were anesthetized with 5% isoflurane (maintained
at 1.5–2.0%) mixed with medical air with 1.5–2 ml/min
flow. Next, animals were positioned in the PET camera
(Focus 220, Siemens Medical Solutions, USA) with the
head in the field of view and in trans-axial position. After
a point-source (Co-57) transmission scan, an automatic
pump was used for the bolus injection of [11C]flumazenil
over 60s. Dynamic PET data were acquired in list mode
for 60 min, starting from the moment the tracer entered
the body. For the PS group, unlabeled flumazenil
(330 nmol in 200 μl of 15% ethanol in saline) was injected
intravenously 5 min before tracer administration [20].
The precursor of [11C]flumazenil and the cold fluma-
zenil were obtained from ABX (art. 1700 and 1710, re-
spectively) in order to ensure high chemical purity
(>95%). The labeled [11C]flumazenil was then synthe-
sized in our laboratory at the UMCG as described else-
where [21]. Moreover, the cold flumazenil compound
was used as standard for the HPLC settings for both the
radiotracer synthesis and for the metabolite analysis. It
was also the compound used for the pre-saturation of
the PS group.
Image processing
List-mode data was reconstructed into 21 frames (6 × 10,
4 × 30, 2 × 60, 1 × 120, 1 × 180, 4 × 300 and 3 × 600 s) in-
cluding all necessary corrections to obtain quantitative
emission images. Sinograms were Fourier rebinned and
reconstructed by a 2D-OSEM algorithm [22] with 4 iter-
ations and 16 subsets, resulting in 128 × 128 × 95 matrix
images, with 0.63 mm pixel width and 0.79 mm slice
thickness. All subsequent PET image analysis, including
pharmacokinetic modeling, was performed with PMOD
v3.7 (PMOD Technologies Ltd., Switzerland).
Table 1 Overview of the animal groups, injected activity, and
mass. Data are expressed as mean ± SD
Injected activity Injected mass Animal weight
Group (MBq) (nmol) (kg)
Tracer dose (n = 10) 59.3 ± 22.6 3.3 ± 2.4 0.273 ± 0.03
Pre-saturated (n = 2) 71.9 and 59.1 1.9 and 5.6 0.300 and 0.295
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Individual dynamic images were automatically core-
gistered to a [11C]flumazenil template [23] pre-aligned
to the Paxinos stereotaxic coordinates system. Bilateral
volumes of interest (VOIs) were extracted from a set of
previously constructed regions [23], including the whole
brain and regions with high GABAA expression (the
frontal cortex and the hippocampus), and low GABAA ex-
pression (cerebellum, medulla, and pons). Due to their
small size and potential vulnerability to spillover effects,
the VOIs from medulla and pons were adapted and re-
duced in order to further separate them from neighboring
high tracer uptake regions. Finally, time-activity curves
(TACs) were generated by projecting the pre-defined
VOIs onto the dynamic images.
Determination of individual metabolite corrected plasma
input curves
For the determination of a metabolite corrected plasma
input function, arterial blood samples of 0.1 ml were ac-
quired (n = 16) and for 2–3 of the time points, larger
samples (0.6 ml) were collected for metabolite analysis.
These 2-3 time points were collected at 5, 10, 15, 30, 45
or 60 min post injection, in order to adequately sample
the metabolites dynamics. Equivalent volumes of saline
were injected to avoid a decrease in blood pressure. For
each sample, blood and plasma were separated and mea-
sured in a gamma counter (LKB-Wallac, Finland) for the
construction of both blood and plasma input curves.
The metabolites were determined by first diluting the
plasma with an equivalent volume of acetonitrile and
mixing it with a vortex for 1 min. Next, it was centri-
fuged at 5.300 rpm for 3 min. The supernatant was then
filtered through a Millipore filter (Millex-HV 4 mm syr-
inge filter, pore 0.45 μm) and an equivalent volume of
water was added, and the volume adjusted to 1 ml with
an HPLC mobile phase. The resulting solution was ana-
lyzed by HPLC using an Alltima RP-C18 column (5 μm,
10 × 250 mm) and a mobile phase of acetonitrile/1 mM
H3PO4 (25/75) at a flow of 5 ml/min.
Next, a population metabolite curve was constructed
by averaging the metabolite samples of the individual
rats and fitting the average curve with a single-
exponential function. Finally, the population average me-
tabolite curve was used for the metabolite correction of
the individual plasma input functions.
Pharmacokinetic modeling
Plasma input models included the one- and two-tissue
compartment models (1TCM and 2TCM, respectively),
and the spectral analysis (SA) [24]. The SA method was
applied with 50 basis functions, the minimum exponen-
tial coefficient set to 0.001 s−1, and the maximum expo-
nential coefficient to 1 s−1. The range of exponential
coefficients was determined based on (1) the range of
VT obtained from 1TCM and 2TCM and (2) the sug-
gested limits of upper and lower bounds as described
previously [25, 26]. The number of grid components
(50) was chosen in order to balance good coverage of
basis functions and computational efficiency. Model fits
were performed with individual metabolite corrected
plasma curves as input functions and a fixed blood vol-
ume fraction of 5% of the whole blood curve. Blood
delay was calculated for the whole brain and subse-
quently fixed for the remaining regions. The distribution
volume (VT) was the parameter of interest for all plasma
input models.
Following previous studies, the pons was considered as
the reference region and its TAC served as input func-
tion for the reference-based models. The full reference
tissue model (FRTM) and two versions of the simplified
reference tissue model, with either one (SRTM[27]) or
two (SRTM-2C[10]) compartments for the reference re-
gion, were applied to the data. The parameter of interest
for the reference tissue-based models was the non-
displaceable binding potential (BPND).
Finally, BPND was also indirectly determined from the
VT estimates of the plasma input models (BPND = (VT/
VT reference)–1 = DVR–1) [28] for method comparison.
Simulations
At first, a set of noiseless TACs (n = 10) was generated
to assess whether model preference was associated to
the level of specific binding relative to the non-specific
signal present in that particular region. For that purpose,
a three-tissue compartment model (3TCM) with varying
levels of specific binding was used for the generation of
TACs, such that these closely matched the shapes and
amplitudes of those seen in the pre-clinical data. First,
an average plasma curve was determined from the ani-
mal data and used as input function. Next, representa-
tive rate constants from the 2TCM fits were determined
and set as starting point for the generation of TACs. K1,
k2, and k4 were set to the average values of the TD group
parameters. Assuming complete receptor blocking in the
PS group, k5 and k6 were defined as the average values
of k3 and k4 of that group. Next, the different binding
levels were generated by varying k3 from 0.2 to 2.6 min
−1. An overview of all micro and macro parameters used
for the simulated TACs can be found in Table 2. Next,
100 TACs per k3 were generated by adding Poisson-like
noise to the noiseless TACs, with zero mean and a
standard deviation corresponding to 5 and 10% of the
average uptake value of the last two frames.
The simulated TACs were subsequently analyzed with
the same models used for the animal data. VT and BPND
from simulated data were compared to the theoretical
values derived from the 3TCM configuration (Table 2).
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Model preference was assessed for the noiseless TACs,
as well as for the different noise levels.
Model comparison and statistical analysis
Statistical data analysis was performed with IBM SPSS
Statistics 22 for both animal and simulated data, and the
results are presented as mean ± standard deviation (SD).
Model preference between 1TCM and 2TCM was
assessed for each region based on the Akaike information
criterion (AIC) [29]. Regional differences in VT values esti-
mated from the three different models (1TCM, 2TCM,
and SA) were tested for significance by repeated measures
ANOVA and subsequent paired t tests. Parameter esti-
mates were also compared between all the six models by
linear regression analysis and Bland-Altman plots. All
results were considered significant when p < 0.05 and,
whenever suited, subsequently corrected for multiple
comparisons by applying the Bonferroni-Holm correction.
Data from the PS group was excluded from the linear
regression analysis. This was done in order to avoid two
clear clusters of different VT magnitudes in the linear
plot, which could affect the correlation values.
Results
Figure 1 shows some representative time-activity curves,
input functions, and metabolite data.
Model preference
Model preference displayed a region-dependent be-
havior for the TD group (Fig. 2). A clear preference
(>70%) for the 1TCM was seen in regions with high
expression of GABAA receptors (frontal cortex and
hippocampus). However, the 2TCM was necessary to
obtain satisfactory fits in regions with low GABAA re-
ceptor expression such as medulla, cerebellum, and
pons (60, 90, and 100% preference, respectively).
Moreover, the spectra of SA analysis provided com-
parable information, with a prevalence of two peaks
(representing two distinct compartments) for the re-
gions of pons, medulla, and cerebellum (100, 70, and
90%). Frontal cortex showed two peaks in only two
animals (20%) and hippocampus in three (30%).
Table 2 Overview of the micro and macro parameters used for
the simulated TACs
Micro parameters Macro parameters
k3 VT DVR–1 BPND
(min−1) (K1/k2) × [1 + (k3/k4) + (k5/k6)] (k3/k4)
0.20 1.44 0 1.17
0.35 1.75 0.22 2.05
0.50 2.06 0.43 2.94
0.65 2.38 0.65 3.82
0.80 2.69 0.87 4.70
0.95 3.00 1.09 5.58
1.10 3.32 1.30 6.47
1.25 3.63 1.52 7.35
1.40 3.95 1.74 8.23
1.55 4.26 1.96 9.11
1.70 4.58 2.18 10.0
1.85 4.89 2.39 10.8
2.00 5.20 2.61 11.7
2.15 5.51 2.83 12.6
2.30 5.83 3.05 13.5
2.45 6.14 3.27 14.4
2.60 6.46 3.48 15.3
Fixed micro parameters (min−1) K1 = 0.8; k2 = 2.25; k4 = 0.17; k5 = 0.15; k6 = 0.08
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Fig. 1 Representative TACs and plasma input function. a Representative TACs of the five regions analyzed in the TD group. b Mean whole blood
and plasma input curves (black and gray circles, respectively) and the 95% confidence intervals as defined by mean ± 1.96*SD displayed in dashed
lines. c Parent plasma curve in percentage, determined as 1—the average percentage of metabolites (solid black line), the 95% confidence
intervals (mean ± 1.96*SD), displayed as dashed lines and the individual samples (black circles)
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In the PS group, 2TCM fits resulted in lower AIC
values for all brain regions (Fig. 2). Moreover, visual in-
spection showed that 1TCM fits were not satisfactory
(Fig. 3a) and, generally, those resulted in an underesti-
mation of both the peak and the tail in the TACs of the
PS group. In the TD group, a similar underestimation
can be seen in regions such as the pons, but not in high-
binding ones such as the frontal cortex (Fig. 3b).
Results from the simulated data displayed a similar
pattern (Fig. 4), with AIC values varying in relation to
different levels of specific binding (small k3). For the
noiseless TACs, AIC values of 1TCM were always
higher than 2TCM fits, and they decreased for in-
creasing k3. When 5% noise was added, AIC for the
2TCM increased with larger k3 such that a small
overlap in model preference was seen for the highest
binding TAC. The addition of 10% noise strengthened
this effect (Fig. 4), with the overlap in AIC values oc-
curring at earlier k3 values.
Distribution volume
Following the AIC results, the 2TCM VT were consid-
ered as reference values for model comparison as it was
the model which provided reliable fits across all brain
regions.
For the TD group, a significant correlation (p < 0.001)
was found between VT from different methods for all re-
gions (Figure 5). Moreover, a significant difference be-
tween VT estimates was found for the low-binding
regions, which corresponded to differences between
1TCM and 2TCM VT (p < 0.005), as well as between
1TCM and SA VT (p < 0.05). An overview of VT values
for each of the models is presented in Table 3.
The Bland-Altman plots also showed region-dependent
differences in VT estimation of the TD group, which were,
percentage-wise, markedly larger for low-density regions
(Fig. 6). The 1TCM VT resulted in small (negative) differ-
ences compared to the 2TCM VT for the frontal cortex
and hippocampus (−0.20 and −0.32%, respectively), while
medulla and pons showed the largest differences between
the two models (−16.9 and −19.1%, respectively).
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Cerebellum could be considered an intermediate region,
both in terms of VT values (Table 3) and in differences be-
tween the models (−8.0%). The VT values estimated from
SA also resulted in region-dependent differences to the
2TCM, with the largest overall differences observed in the
frontal cortex (−5.16%) and the smallest seen in the pons
(0.44%), as can be observed in Fig. 6b. However, the vari-
ability in these differences was higher than what was seen
between 1TCM and 2TCM, corresponding to wider 95%
limits of agreement (Table 4).
The Bland-Altman plot of the simulated data showed
a bias pattern comparable to what was observed in the
animal data (Fig. 7). VT values from the SA method
demonstrated an overall constant and small negative
bias (−0.76%) compared to theoretical values. For the
1TCM and the 2TCM, the overall bias was −19.1 and
−2.94%, respectively, and it was also strongly dependent
on the level of binding present in the TAC (Fig. 7).
Indirect and direct binding potential
DVR–1 from the 2TCM were considered as reference
values for model comparison based on model preference
results across brain regions. An overview of BPND values
estimated from each model (direct and indirect) can be
found in Table 5.
Compared to the other models, 1TCM DVR–1
showed the largest overall difference to 2TCM DVR–
1 values (26.9%), with 95% limits of agreement reach-
ing more than 40% for all regions (Table 4). Estimates
of DVR–1 from SA demonstrated an overall small
difference to 2TCM DVR–1 values (−4.21%) but with
wide 95% limits of agreement (−39.8 to 31.37%), indi-
cating an overall higher variability in parameter esti-
mation (Fig. 6). All reference models (FRTM, SRTM,
and SRTM-2C) underestimated BPND (differences of
−13.9, −15.9, and −23.8%, respectively) in comparison
with DVR–1 from the 2TCM.
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Simulated data exhibited a similar pattern in the
Bland-Altman plot (Fig. 7b). FRTM, SRTM, and SRTM-
2C resulted in an underestimation of BPND, with a
(negative) bias (−0.75, −1.03, and −0.88%, respectively)
that showed a slight increase for higher levels of binding
(larger k3). SA displayed negligible bias (0.14%), inde-
pendent of the binding level. DVR–1 from both the
1TCM and the 2TCM resulted in a positive bias, with
40.5% BPND overestimation for the 1TCM and a 5.6%
overestimation for the 2TCM.
Discussion
The 1TCM and the SRTM were previously established
as methods of choice for the quantification of [11C]flu-
mazenil in human studies [13]. Since a direct translation
from the clinical to the pre-clinical setting, or vice-versa,
is not recommendable, an assessment must be per-
formed to determine whether the clinically used 1TCM
and SRTM are also suited for the analysis of [11C]fluma-
zenil in animal studies. Therefore, the present study
evaluated different pharmacokinetic models for the
quantification of [11C]flumazenil binding specifically for
the rat brain.
The distribution pattern seen in the TD group was
comparable to what was seen in human studies, as well
as autoradiography studies of the rat brain [20, 30], dis-
playing higher uptake in the cortical regions and the
lowest in pons and medulla. However, it is interesting to
note that the VT in the pons was more than two times
higher than what has been reported in human studies
[13, 31]. In fact, both medulla and pons of the TD group
exhibited a relatively high VT (VT > 2) for low-density
regions, independently of the model used for quantifi-
cation. Since these high VT values could have been
related to spillover effects from neighboring regions,
the delineation of pons and medulla VOIs from the
original atlas was limited in order to further separate
the regions and minimize the potential spillover.
Moreover, pre-saturation with cold flumazenil resulted
in a clear decrease of the VT in the pons of approxi-
mately 35%, as compared with the VT values observed
in the TD group. These results suggest the presence
of a substantial level of specific binding in the rat
pons, which is in line with a considerable displace-
ment of a fluorinated version of flumazenil in that re-
gion, reported in a study by Dedeurwaerdere et al.
[20]. For this reason, the pons cannot be considered a
“true reference region” in rat studies, and the estima-
tion of BPND from the reference tissue-based models
are negatively biased.
In terms of model preference, regions with high dens-
ity of GABAA receptors (frontal cortex and hippocam-
pus) followed the same behavior as what has been
described in humans. These regions showed a strong
(70%) preference for the 1TCM according to AIC and in
accordance with the spectra of SA analysis. However, a
closer look into the results suggests that the 2TCM re-
sulted in similar AIC values (e.g., 143.7 ± 7.1 for the
1TCM against 144.8 ± 9.6 for the 2TCM in the frontal
cortex), with both models providing similar VT values.
In fact, no statistical differences were found between
1TCM and 2TCM VT values for those regions. Such
findings are in line with what has previously been re-
ported for human studies [11], where the authors state
that expanding from a 1TCM to a 2TCM configuration
did not improve the quality of the fit in high-density re-
gions. These observations could be explained by the
relative size between specific and non-specific compart-
ments for these regions. In the presence of high levels of
binding, the contribution of the non-specific compo-
nent to the overall signal becomes too small, and the
two compartments cannot be kinetically distinguished.
Our results suggest that the 1TCM could be applied
for these regions due to its reduced complexity com-
pared to the 2TCM, despite the fact that both models
provide similar AIC, VT, and BPND values. However,
applying the same model to all regions of interest is
advisable. In that way, potential individual or group
differences in estimated parameters are not affected
by differences in model choice and would therefore
better represent any underlying physiological changes.
Thus, the decision as to which of the two models
(1TCM and 2TCM) should be applied must also in-
corporate the performance of these models for the
low-density regions.
Table 3 Regional distribution volume (VT) estimates from the
three different methods for each of the groups. Data are
expressed as mean ± SD for the tracer dose group (n = 10) and
as individual values for the pre-saturated group (n = 2)
VT
Region 2TCM 1TCM SA
Tracer dose (n = 10)
Frontal cortex 7.81 ± 1.10 7.80 ± 2.38 7.15 ± 1.17
Hippocampus 6.86 ± 0.94 6.84 ± 2.08 6.55 ± 0.95
Cerebellum* 4.44 ± 0.67 4.11 ± 1.24 4.33 ± 0.65
Medulla* 2.77 ± 0.48 2.35 ± 0.71 2.66 ± 0.39
Pons* 2.54 ± 0.40 2.10 ± 0.61 2.45 ± 0.33
Pre-saturated (n = 2)
Frontal cortex 1.23 and 1.10 0.67 and 0.73 1.00 and 0.89
Hippocampus 1.07 and 0.92 0.60 and 0.62 1.09 and 0.68
Cerebellum 0.98 and 0.91 0.52 and 0.58 1.00 and 0.69
Medulla 0.89 and 0.80 0.46 and 0.56 0.69 and 0.83
Pons 0.99 and 0.88 0.55 and 0.59 0.80 and 0.72
*Significant differences were found in these regions between 1TCM and 2TCM
estimates (p < 0.005) as well as between 1TCM and SA (p < 0.05)
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Indeed, one important finding of this study was the
observation that the 1TCM is not suited for the quantifi-
cation of low-density regions. The first indication is the
preference displayed by these regions for the 2TCM,
supported by AIC values, visual inspection of TAC fits
(Fig. 3a, b), and kinetic spectra from SA. In fact, espe-
cially for the pons, the 1TCM was not preferred for any
of the animals of the TD group. Moreover, VT values
were significantly different between models for low-
binding regions, demonstrating that the various models
cannot be used interchangeably in this case. Instead, the
2TCM provided the best fits, while the 1TCM consist-
ently underestimated VT compared to those from
2TCM. While the SA provided VT values similar to
those from 2TCM, the difference between the methods
was still statistically significant and the standard devi-
ation observed in this method was the largest of the
three. This variability in the VT estimates could be ex-
plained by the known sensitivity of this method to noise
[25], but it could also be related to the wide definition of
the basis function settings used in the study. Therefore,
based on the present results, SA should be considered
carefully for the analysis of rat data. It is interesting to
notice, however, the intermediate behavior displayed by
cerebellum in terms of model performance. In this re-
gion, although the model preference based on AIC
strongly favored the 2TCM, differences between 1TCM
or SA and 2TCM-derived VT values were not so marked.
This could be related to the intermediate levels of α sub-
units in this region [30].
Regarding the PS group, the analysis of model prefer-
ence and performance produced results similar to those
of the low-density regions, with lower AIC values for the
2TCM. These results were surprising, as the pre-
saturation was expected to completely block the second
(specific) compartment [32] and to leave only the first
compartment intact (i.e., the compartment related to the
free and non-displaceable components). Due to the simi-
larity in model preference between PS group and low-
density regions of the TD group, it was hypothesized
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Fig. 6 Bland-Altman plots of agreement of VT and BPND estimates of different models. Bland-Altman plots for analysis of agreement in VT and
BPND values between different models. On the top, Bland-Altman plots for agreement between VT estimates from SA and 2TCM (a) and from
1TCM and 2TCM (b). On the bottom, a Bland-Altman plot for agreement between BPND estimates from five different methods in comparison with
DVR–1 from the 2TCM. The dashed lines represent zero difference and the y-axis is expressed in %difference. More information on the %difference
and 95% limits of agreement for each method can be found in Table 4
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Table 4 Bland-Altman analysis of VT, DVR–1 and BPND of animal data
Animal data
% difference (95% L.A.)
VT 1TCM SA 2TCM
a
Frontal cortex −0.20 (−1.93 to 1.52) −5.16 (−18.2 to 7.87) –
Hippocampus −0.32 (−2.50 to 1.84) −1.43 (−10.0 to 7.15) –
Cerebellum −8.01 (−19.0 to 3.01) −1.31 (−5.42 to 2.78) –
Medulla −16.9 (−34.0 to 0.24) −3.54 (−14.4 to 7.32) –
Pons −19.1 (−35.9 to −2.37) 0.44 (−24.2 to 25.0) –
Overall −8.91 (−28.4 to 10.5) −2.20 (−16.2 to 11.8) –
DVR–1 1TCM SA
Frontal cortex 26.7 (4.74 to 48.7) −9.01 (−53.3 to 35.3) –
Hippocampus 28.3 (5.72 to 50.8) −2.53 (−31.5 to 26.4) –
Cerebellum 24.1 (4.75 to 43.2) 1.70 (−22.8 to 26.2) –
Medulla 28.5 (−44.7 to 101) −7.02 (−49.3 to 35.3) –
Pons – – –
Overall 26.9 (−12.6 to 66.4) −4.21 (−39.8 to 31.4) –
BPND FRTM SRTM SRTM-2C
Frontal cortex −12.5 (−20.3 to −4.67) −13.8 (−21.5 to 6.16) −7.74 (−15.3 to −0.22)
Hippocampus −11.0 (−17.9 to −4.05) −12.5 (−19.6 to −5.40) −7.59 (−12.9 to −2.24)
Cerebellum −6.54 (−15.9 to 2.82) −9.58 (−22.3 to 3.14) −13.7 (−29.1 to 1.72)
Medulla −25.6 (−152 to 101) −27.7 (−134 to 78.8) −66.2 (−151 to 18.8)
Pons – – –
Overall −13.9 (−76.7 to 48.9) −15.9 (−69.6 to 37.8) −23.8 (−88.0 to 40.4)
aThe 2TCM is the model of reference for comparisons. The pons is the reference region for reference-based modeling
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Fig. 7 Bland-Altman plots of parameter agreement for simulated TACs. Bland-Altman plots for the analysis of parameter agreement for simulated
TACs. a Bland-Altman plot of agreement between VT estimates from 1TCM (black square), 2TCM (gray square), and SA (gray-filled diamond)
compared to theoretical values. b Bland-Altman plot of agreement between DVR–1 and BPND estimates from different methods compared
to theoretical values. The dashed lines represent zero difference and the y-axis is expressed in %bias
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that model preference is affected by the levels of specific
binding present in a particular region. Therefore, simu-
lated data were generated in order to substantiate this
hypothesis, and the results obtained from the analysis
seemed to support it. More specifically, both the 1TCM
and the 2TCM showed good agreement to theoretical
values for TACs with high VT, and the bias increased for
TACs with lower VT. Moreover, the TACs with high
binding and therefore high VT values showed smaller dif-
ferences in AIC between 1TCM and 2TCM fits, while
this difference increased for lower VT values. The differ-
ences in model preference and performance seen between
the simulated and the animal datasets can be explained by
the noiseless character of the generated TACs.
As previously mentioned, the rat pons demonstrated a
considerable level of specific binding. Coupled with the
underestimation in VT seen from the 1TCM, these re-
sults could explain the poor performance of reference
models. First, the specific binding seen in the pons re-
sults in an underestimation of BPND by direct estimation
based on reference models. Second, the fact that the
pons is better described by a 2TCM directly violates one
of the assumptions used in the FRTM and SRTM, where
the reference region should be adequately described by a
1TCM configuration [27]. Our results confirmed the
violation of this assumption, and both SRTM and FRTM
were affected in a similar way, displaying similar differ-
ences in BPND estimates as compared to DVR–1 from
the 2TCM. Such an effect has larger impact for high-
binding regions and results in considerable underestima-
tion of BPND in absolute terms [33]. In order to allow a
different configuration for the reference tissue, the
SRTM-2C was also tested. Interestingly, the SRTM-2C
showed a small improvement compared to the other ref-
erence models for high-binding regions (Table 3). In-
deed, fits of those regions showed lower AIC values for
the SRTM-2C compared to the SRTM (data not shown).
However, the 2TCM-2C resulted in larger differences to
2TCM DVR–1 for cerebellum and medulla, which could
be due to a combination between low amounts of spe-
cific binding and the larger number of model parame-
ters, resulting in increased uncertainty in parameter
estimation. In that context, SRTM represented the most
robust reference model for the animal data. Yet, it
should be mentioned that both plasma input-derived
DVR–1 and SRTM-based BPND estimates will be nega-
tively biased by the presence of specific binding in the
reference region (pons), as discussed below. Moreover, it
is also important to notice that although radiometabo-
lites have the potential to introduce bias in estimation of
model parameters, the reported major metabolites of
[11C]flumazenil are polar compounds and, as such, are
expected not to enter the brain [34].
In summary, the quantification of [11C]flumazenil
binding in rat studies should not be performed with the
1TCM, as it is the case in human studies. In fact, the
2TCM is required for an accurate VT estimation in low-
density regions such as the pons, and it provides VT
values equivalent to 1TCM for the high-density regions.
In the case of reference-based modeling, the use of the
pons as a reference region requires careful consideration.
Since the rat pons demonstrated a considerable level of
specific binding, any direct estimation of BPND via refer-
ence models will suffer from underestimation of tracer
binding. However, the pons might be considered a
pseudo-reference region [35], provided the experimental
conditions and physiological state of the animals does
not affect tracer delivery and binding in this region
across the different groups. Such a condition might not
be met for different study designs. In those cases, a first
validation using plasma input kinetic analysis in a sub-
sample of the data is required in order to ensure that
pons could be used as pseudo-reference region. Once
the pons has been validated as a pseudo-reference
region, reference-based modeling could be useful in pro-
viding a simple and robust alternative for BPND estima-
tion without arterial sampling. In that case, SRTM
would be preferable due to its robust implementation,
smaller number of fit parameters, and good agreement
to DVR–1 from the 2TCM.
Conclusions
This study showed that [11C]flumazenil kinetics is differ-
ent between rats and humans, and indicate that kinetic
models used in clinical studies are not necessarily suited
in the pre-clinical setting. For high-density regions, both
Table 5 Regional binding potential (BPND or DVR–1) estimates from the different methods for the tracer dose group (n = 10). Data
are expressed as mean ± SD
DVR–1 BPND
Region 2TCM 1TCM SA FRTM SRTM SRTM-2C
Tracer dose
Frontal cortex 2.09 ± 0.23 2.75 ± 0.36 1.94 ± 0.42 1.84 ± 0.20 1.92 ± 0.20 1.93 ± 0.20
Hippocampus 1.71 ± 0.21 2.28 ± 0.26 1.69 ± 0.32 1.53 ± 0.19 1.51 ± 0.19 1.59 ± 0.18
Cerebellum 0.75 ± 0.08 0.96 ± 0.14 0.77 ± 0.11 0.70 ± 0.07 0.68 ± 0.08 0.65 ± 0.08
Medulla 0.09 ± 0.03 0.12 ± 0.03 0.08 ± 0.03 0.08 ± 0.07 0.07 ± 0.04 0.05 ± 0.03
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1TCM and 2TCM estimated comparable VT values and
resulted in similar quality of fits (AIC). However, the ap-
plication of the 2TCM in low-density regions resulted in
higher quality of fits, both from visual inspection and
AIC values. Moreover, the clinically applied 1TCM was
not able to satisfactorily fit the data (visual inspection)
of those regions, nor in the case of pre-saturation with
cold flumazenil. Therefore, the 2TCM is the preferred
plasma input model for the quantification of [11C]fluma-
zenil in the rat brain. Among the various reference tissue
models tested, SRTM was preferred providing BPND esti-
mates in good agreement with plasma input 2TCM
based DVR–1 values.
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